Ohio State Navbar

Clinical Trials


The talented faculty within the Division of Medical Oncology are proud to be a part of the Comprehensive Cancer Center Network  and one of only five centers in the nation that is approved for Phase I and Phase II clinical Trials. Our team  currently has numerous clinical trials open to accrual  focusing on cancers ranging from non-small cell lung cancer, pancreatic cancer, metastatic breast cancer, metastatic melanoma and much more.  If you are interested in learning more about our current clinical trials, please use the search feature for more information.

Current Clinical Trials

Below are a few of the recently opened cancer clinical trials available at Ohio State.

If you would like more information or are interested in referring a patient to one of these trials, call The James Line at 1-800-293-5066.

Be sure to check out our cancer clinical trials search tool by visiting cancer.osu.edu

(*) Asterisk denotes trial listed is offered only at Ohio State.

 

Breast

*Radiation Response With MRI/CT Preop Partial Breast Irradiation in Prone Position for Early-Stage Breast Cancer
OSU-13282 (Julia White, MD)

Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A011202 (Doreen Agnese, MD)

Compassionate Use of ABT 888 for a Patient With Metastatic Breast Cancer
OSU-14241 (Maryam Lustberg, MD)

Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
OSU-14043 (Robert Wesolowski, MD)

Phase I Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases
NRG-BR001 (Jose Bazan, MD)

Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
OSU-13079 (Lisa Yee, MD)

Gastrointestinal

*Phase II Study of Ponatinib for Advanced Cancers With Genomic Alterations in FGFR and Other Genomic Targets
OSU-14078 (Sameek Roychowdhury, MD, PhD)

Neoadjuvant GMCI(TM) Plus Modified Folfirinox and Chemoradiation for Advanced Non-Metastatic Pancreatic Adenocarcinoma
OSU-14117 (Mark Bloomston, MD) 

Phase III, Randomized, Double-blind, Placebo-Controlled, Multicenter Study of Maintenance Olaparib Monotherapy in Patients With gBRCA-Mutated Metastatic Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
OSU-14281 (Tanios Bekaii-Saab, MD)

Phase IIb, Nonrandomized, Open-Label Trial With Mouse Renal Adenocarcinoma (RENCA) Cell-Containing Agarose-Agarose Macrobeads Compared With Best Supportive Care in Patients With Treatment-Resistant, Metastatic Colorectal Carcinoma
OSU-13024 (William Carson, MD)

Randomized Phase II Trial of Single-Agent MEK Inhibitor Trametinib (GSK1120212) vs. 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
SWOG-S1310 (Tony Bekaii-Saab, MD)

Phase II, Multicenter, Single-Arm Study of Oral BGJ398 in Adult Patients With Advanced or Metastatic Cholangiocarcinoma With FGFR2 Gene Fusions or Other FGFR Genetic Alterations Who Failed or Are Intolerant to Platinum-Based Chemotherapy
OSU-14106 (Tony Bekaii-Saab, MD)

Phase II Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors
OSU-14006 (Richard Goldberg, MD)

Phase Ib Clinical Study of BBI608 in Combination With Gemcitabine and Nab-Paclitaxel in Adult Patients With Metastatic Pancreatic Adenocarcinoma
OSU-14146 (Tony Bekaii-Saab, MD)

Genitourinary

Phase IB, Open-Label, Dose-Finding Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Axitinib (AG-013736) in Combination With MK-3475 in Patients With Advanced Renal Cell Cancer OSU-14168 (Thomas Olencki, DO)

Phase III, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab vs. Sunitinib Monotherapy in Subjects With Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
OSU-14247 (Thomas Olencki, DO)

Phase I, Open-label, Multicenter, Dose-Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies
OSU-14108 (Amir Mortazavi, MD)

Randomized, Open-Label, Phase IIa Study Evaluating the Efficacy and Safety of Radium-223 Dichloride in Combination With Abiraterone Acetate or Enzalutamide in Subjects With Castration-Resistant Prostate Cancer (CRPC) Who Have Bone Metastases
OSU-13256 (J. Paul Monk, MD)

Gynecologic

Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK1120212) in
Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer
GOG-0281 (David O'Malley, MD)

Phase I Study of MLN0128 and Bevacizumab in Patients With Recurrent Glioblastoma and Other Solid Tumors
OSU-14154 (John Hays, MD, PhD)

Thoracic

*Phase II Study of Single Agent Selinexor (KPT-330) in Patients With Relapsed Small Cell Lung Cancer OSU-14136 (Erin Bertino, MD

TIGER-3: Phase III, Open-Label, Multicenter, Randomized Study of Oral Rociletinib (CO-1686) Monotherapy vs. Single-Agent Cytotoxic Chemotherapy in Patients With Mutant EGFR Non-Small Cell Lung Cancer (NSCLC) After Failure of at Least 1 Previous EGFR-Directed Tyrosine Kinase Inhibitor (TKI) and Platinum-Doublet Chemotherapy
OSU-15013 (Gregory Otterson, MD)

Phase II Trial Combining Hypofractionated Radiation Boost With Conventionally Fractionated Chemoradiation in Locally Advanced Non-Small-Cell Lung Cancer Not Suitable for Surgery
OSU-14091 (Terrance Williams, MD, PhD)

Phase II/III Biomarker-Driven Master Protocol for Second-Line Therapy of Squamous Cell Lung Cancer (Screening Step)
SWOG-S1400 (Erin Bertino, MD)

Phase I, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI0639 as a Single Agent and in Combination Therapy in Adult Subjects With Advanced Solid Tumors, Including Small-Cell Lung Cancer
OSU-14044 (Erin Bertino, MD)

Phase I Study of Trametinib in Combination With Chemoradiation for Kras Mutant Non-Small-Cell Lung Cancer
OSU-14034 (Meng Welliver, MD)

Head and Neck

Phase II Clinical Trial of Single Agent Pembrolizumab (MK-3475) in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Who Have Failed Platinum and Cetuximab

OSU-14232 (Maura Gillison, MD, PhD)

Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein-Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
NRG-HN001 (Dukagjin Blakaj, MD)

Randomized Phase II Trial for Patients With p16-Positive, Non-Smoking-Associated, Locoregionally advanced Oropharyngeal Cancer
NRG-HN002 (Maura Gillison, MD, PhD)

Melanoma

Randomized Phase II Trial of Intermittent vs. Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E/K Mutant Melanoma
SWOG-S1320 (Kari Kendra, MD, PhD)

Randomized Phase II Study of Sequential Biotherapy With Aflibercept and High-Dose IL-2 vs. High-Dose IL-2 alone in Patients With Inoperable Stage III or Stage IV Melanoma: Efficacy and Biomarker Study
OSU-14083 (Thomas Olencki, DO)

Sarcoma

SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma and Ewing/Ewing-like Sarcomas
OSU-14056 (David Liebner, MD)



Updated: 7/30/15